The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Edin, Sofia ^a   Wikberg, Maria L ^a   Dahlin, Anna M ^a   Rutegård, Jörgen ^a   Öberg, Åke ^a   Oldenborg, Per Arne ^a   Palmqvist, Richard ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD163 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE MIGRATION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RATING SCALE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; COLON; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MICROSATELLITE INSTABILITY; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; PROGNOSIS; RECEPTORS, CELL SURFACE; RECTUM;

EID: 84867504992     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047045     Document Type: Article

References (65)

1. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
2. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, et al. (2009) Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214: 761-777.
3. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P, (2010) Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 29: 243-248.
4. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A, (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25: 315-322.
5. Qian BZ, Pollard JW, (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
6. Sica A, Allavena P, Mantovani A, (2008) Cancer related inflammation: the macrophage connection. Cancer Lett 267: 204-215.
7. Sica A, Schioppa T, Mantovani A, Allavena P, (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42: 717-727.
8. Siveen KS, Kuttan G, (2009) Role of macrophages in tumour progression. Immunol Lett 123: 97-102.
9. Solinas G, Germano G, Mantovani A, Allavena P, (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86: 1065-1073.
10. Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, et al. (2009) Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 27: 3330-3337.
11. Makitie T, Summanen P, Tarkkanen A, Kivela T, (2001) Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 42: 1414-1421.
12. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, et al. (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625-4629.
13. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, et al. (2005) Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14: 425-431.
14. Hamada I, Kato M, Yamasaki T, Iwabuchi K, Watanabe T, et al. (2002) Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res 22: 4281-4284.
15. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, et al. (2000) Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 7: 263-269.
16. Chai CY, Chen WT, Hung WC, Kang WY, Huang YC, et al. (2008) Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol 61: 658-664.
17. Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundstrom J, et al. (2012) Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer 131: 864-873.
18. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, et al. (2007) High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13: 1472-1479.
19. Lackner C, Jukic Z, Tsybrovskyy O, Jatzko G, Wette V, et al. (2004) Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch 445: 160-167.
20. Zhou Q, Peng RQ, Wu XJ, Xia Q, Hou JH, et al. (2010) The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med 8: 13.
21. Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, et al. (2009) Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 9: 65.
22. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, et al. (2003) The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 23: 5015-5022.
23. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, et al. (2000) Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 17: 445-451.
24. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, et al. (2000) Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 60: 5857-5861.
25. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, et al. (2005) Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23: 953-964.
26. Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, et al. (2008) High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer 98: 1118-1124.
27. Takanami I, Takeuchi K, Kodaira S, (1999) Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 57: 138-142.
28. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, et al. (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 23: 8959-8967.
29. Dai F, Liu L, Che G, Yu N, Pu Q, et al. (2010) The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 10: 220.
30. Hashimoto I, Kodama J, Seki N, Hongo A, Miyagi Y, et al. (2000) Macrophage infiltration and angiogenesis in endometrial cancer. Anticancer Res 20: 4853-4856.
31. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, et al. (2004) Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 24: 3335-3342.
32. Salvesen HB, Akslen LA, (1999) Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 84: 538-543.
33. Popat S, Hubner R, Houlston RS, (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609-618.
34. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, et al. (2002) CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122: 1376-1387.
35. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, et al. (2007) Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104: 18654-18659.
36. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96: 8681-8686.
37. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, et al. (2004) BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53: 1137-1144.
38. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS, (2006) CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 8: 582-588.
39. Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklof V, et al. (2010) The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 16: 1845-1855.
40. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793.
41. Allen M, Louise Jones J, (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 223: 162-176.
42. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A, (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073-1081.
43. Fridman WH, Pages F, Sautes-Fridman C, Galon J, (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298-306.
44. Ogino S, Galon J, Fuchs CS, Dranoff G, (2011) Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 8: 711-719.
45. Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, et al. (2011) Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 52: 643-650.
46. Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, et al. (2011) Tumor-Associated Macrophages (TAMs) Form an Interconnected Cellular Supportive Network in Anaplastic Thyroid Carcinoma. PLoS One 6: e22567.
47. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, et al. (2010) Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 101: 1913-1919.
48. Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, et al. (2011) Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 102: 1424-1431.
49. Komohara Y, Ohnishi K, Kuratsu J, Takeya M, (2008) Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 216: 15-24.
50. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, et al. (2011) Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer. J Surg Res15 167(2):: e211-9.
51. Ma J, Liu L, Che G, Yu N, Dai F, et al. (2010) The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10: 112.
52. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, et al. (2007) Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 5: 62.
53. Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, et al. (2010) Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 60: 278-283.
54. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P, (2009) Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33: 118-126.
55. Pander J, Heusinkveld M, Van der Straaten T, Jordanova ES, Baak-Pablo R, et al. (2011) Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 17: 5668-1673.
56. Shabo I, Stal O, Olsson H, Dore S, Svanvik J, (2008) Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer 123: 780-786.
57. van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, et al. (2010) Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 127(4):: 899-909.
58. Mosser DM, Edwards JP, (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
59. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, et al. (2012) Colorectal cancer: a tale of two sides or a continuum? Gut 61: 794-797.
60. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, et al. (2012) Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61: 847-854.
61. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, et al. (2002) Short-term preoperative radiotherapy interferes with the determination of pathological parameters in rectal cancer. J Pathol 197: 20-27.
62. Weber B, Saurer L, Mueller C, (2009) Intestinal macrophages: differentiation and involvement in intestinal immunopathologies. Semin Immunopathol 31: 171-184.
63. Kloor M, Michel S, von Knebel Doeberitz M, (2010) Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 127: 1001-1010.
64. Banerjea A, Bustin SA, Dorudi S, (2005) The immunogenicity of colorectal cancers with high-degree microsatellite instability. World J Surg Oncol 3: 26.
65. Bauer K, Michel S, Reuschenbach M, Nelius N, von Knebel Doeberitz M, et al. (2011) Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Fam Cancer 10(3):: 557-65.